Establishing test-retest reliability of an adapted [F-18]fallypride imaging protocol in older people

TY - JOUR

T1 - Establishing test-retest reliability of an adapted [F-18]fallypride imaging protocol in older people

AU - Dunn, Joel T.

AU - Clark-Papasavas, Chloe

AU - Marsden, Paul

AU - Baker, Stacey

AU - Cleij, Marcel

AU - Kapur, Shitij

AU - Kessler, Robert

AU - Howard, Robert

AU - Reeves, Suzanne J.

PY - 2013/7

Y1 - 2013/7

N2 - [F-18]fallypride is a high-affinity dopamine D2/3 receptor tracer with the ability to reliably quantify D2/3 receptor sites in both striatal and corticolimbic regions. The translational potential of [F-18]fallypride imaging is, however, limited by the lengthy scanning sessions (60-80 minutes duration over a total of 3-4 hours) required by current protocols. The aims of our study were to adapt [F-18]fallypride imaging for use in clinical populations with neurological and neuropsychiatric disorders, by reducing the duration of individual scanning sessions; and to establish the reproducibility and reliability of our adapted protocol in healthy older people. Eight participants (five male and three female; mean age = 75.87 +/- 4.39 years) were scanned twice, 4-6 weeks apart. [F-18]fallypride binding potential was determined from image data collected during three sampling times: 0-30; 60-90; and 210-240 minutes post injection. High reproducibility and reliability (test-retest variability 0.8) were observed in all but the prefrontal regions, and remained so when sampling times were reduced to 20 minutes (0-20; 70-90; 220-240 minutes). The adapted protocol is feasible for use across neuropsychiatric disorders in which dopamine has been implicated and is sufficiently sensitive to detect within-subject changes between 2.7% and 5.5% in striatal and limbic regions.

AB - [F-18]fallypride is a high-affinity dopamine D2/3 receptor tracer with the ability to reliably quantify D2/3 receptor sites in both striatal and corticolimbic regions. The translational potential of [F-18]fallypride imaging is, however, limited by the lengthy scanning sessions (60-80 minutes duration over a total of 3-4 hours) required by current protocols. The aims of our study were to adapt [F-18]fallypride imaging for use in clinical populations with neurological and neuropsychiatric disorders, by reducing the duration of individual scanning sessions; and to establish the reproducibility and reliability of our adapted protocol in healthy older people. Eight participants (five male and three female; mean age = 75.87 +/- 4.39 years) were scanned twice, 4-6 weeks apart. [F-18]fallypride binding potential was determined from image data collected during three sampling times: 0-30; 60-90; and 210-240 minutes post injection. High reproducibility and reliability (test-retest variability 0.8) were observed in all but the prefrontal regions, and remained so when sampling times were reduced to 20 minutes (0-20; 70-90; 220-240 minutes). The adapted protocol is feasible for use across neuropsychiatric disorders in which dopamine has been implicated and is sufficiently sensitive to detect within-subject changes between 2.7% and 5.5% in striatal and limbic regions.

KW - dopamine

KW - [F-18]fallypride

KW - imaging

KW - receptors

KW - reliability

KW - test-retest

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - EXTRASTRIATAL DOPAMINE-D-2 RECEPTORS

KW - HUMAN-BRAIN

KW - F-18 FALLYPRIDE

KW - ANTIPSYCHOTIC-DRUGS

KW - D-2/D-3 RECEPTORS

KW - PET

KW - OCCUPANCY

KW - RELEASE

KW - BINDING

KW - Acknowledged-BRC

KW - Acknowledged-BRC-13/14

U2 - 10.1038/jcbfm.2013.55

DO - 10.1038/jcbfm.2013.55

M3 - Article

SN - 0271-678X

VL - 33

SP - 1098

EP - 1103

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

IS - 7

ER -